COVID Medicines Delivery Unit (CMDU) Update for patients in the highest risk categories
COVID Medicines Delivery Unit (CMDU) Update for patients in the highest risk categories
In response to changes to the NICE guidance the CMDU service will be available from 1st June 2025 to the following cohort of patients testing positive for COVID-19:
• patients who fall into one of the high risk subgroups, as defined in Section 5 of NICE TA878 (please see link below for details of these cohorts)
(these patients will be eligible for consideration of treatment with Paxlovid 1st line, sotrovimab 2nd line and molnupiravir 3rd line)
No other cohorts of patients are eligible for consideration of treatment if they test positive with COVID-19 from 1st June 2025 (this is a reduction in eligible cohorts and no longer includes residents in care homes in line with the updated NICE TA guidance).
Key points to note:
• The service requires patients who fall into the cohort as defined in Section 5 of NICE TA878, testing positive for COVID-19 to proactively call 03000 24 0000 for assessment (this number will be available 24 hours a day 7 days a week, though depending on time of contact there may be a need to await a call back within 24 hours to be clinically triaged).
• Patients who fall into one of the cohorts as defined in Section 5 of NICE TA878 have access to free NHS lateral flow device tests via Community Pharmacies who have signed up to the NHS lateral flow device tests supply service for patients potentially eligible for COVID-19 treatment. Use this link - COVID-19 testing - NHS to find out which Community Pharmacies are offering this service.
Published on 2 June 2025